{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/mi-secondary-prevention/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"e9a32a50-5bdc-5fc0-8ecb-152881ffa7ad","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 5c27677c-448d-4570-839e-1422a8b9f974 --><h2>Changes</h2><!-- end field 5c27677c-448d-4570-839e-1422a8b9f974 -->","summary":null,"htmlStringContent":"<!-- begin item e8e66203-d3dc-4883-815d-576d44b743f1 --><!-- begin field 046c84df-7cee-46dc-bfd0-41b854b22d7e --><p><strong>May 2020</strong> — minor update. Prescribing information has been added in response to the National Institute for Health and Care Excellence (NICE) <em>COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19</em> to reflect the advice during the COVID-19 pandemic.</p><p><strong>February to March 2019 </strong>— reviewed. A literature search was conducted in February 2019 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone restructuring. No major changes to the recommendations have been made.</p><!-- end field 046c84df-7cee-46dc-bfd0-41b854b22d7e --><!-- end item e8e66203-d3dc-4883-815d-576d44b743f1 -->","topic":{"id":"10808f6c-5a83-5526-84e2-5998dee92475","topicId":"0b3a22ee-885a-43aa-8d4b-a290dc2afbcc","topicName":"MI - secondary prevention","slug":"mi-secondary-prevention","lastRevised":"Last revised in May 2020","chapters":[{"id":"6d17bc7f-3ed1-5a79-b4f4-8e9dc752c658","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a57b961c-8bba-5c02-8844-b6307b89222c","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"dc552ddd-7106-5f5f-a7d9-4b2d6f80e1fa","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"e9a32a50-5bdc-5fc0-8ecb-152881ffa7ad","slug":"changes","fullItemName":"Changes"},{"id":"d4c6dcc6-12c6-52a1-957d-47a931a225ec","slug":"update","fullItemName":"Update"}]},{"id":"8c06d36f-1d73-5741-981b-5ed3cc16b7c2","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"cd13560d-8bec-5902-9a9e-2ce26eaa9028","slug":"goals","fullItemName":"Goals"},{"id":"b9d35945-0a30-523a-9ded-6a2ea7f5a79a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5c84a4ff-a034-50b3-b1a3-7cfecfb1e65c","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"02b0b701-c0f0-542f-b958-8d30a81301fc","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f516bbb5-ea19-5f8f-be12-d8f550493156","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"cf211bbf-df50-54c9-b204-ef227db8c62f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"3ddc8181-0420-5ae4-8326-2d5ef700203a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f303e07d-da7d-5073-b00b-f3dd008f2594","slug":"definition","fullItemName":"Definition"},{"id":"45810734-c13c-5bbd-b314-88dcbfd54c57","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5488a58d-1964-5d60-a54e-a420fd0daeff","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"b05c9d6f-fae2-5624-bc64-e5456fa46e84","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"2dd1d8e3-398b-5765-b249-43150874e311","fullItemName":"Management","slug":"management","subChapters":[{"id":"6854ca49-f0af-50f1-8fd3-a6bb900b4bc4","slug":"secondary-prevention","fullItemName":"Scenario: Secondary prevention"}]},{"id":"a4fb09c9-df2a-5800-954a-58fe23af6127","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"e43e8d70-7611-5939-94cb-7cc18a3950a6","slug":"ace-inhibitors","fullItemName":"ACE inhibitors"},{"id":"0220c0cb-0802-5bfa-9d8b-f767f73dbea1","slug":"antiplatelet-treatments","fullItemName":"Antiplatelet treatments"},{"id":"a6c13387-db91-5f87-9795-c95a1be0a245","slug":"beta-blockers","fullItemName":"Beta blockers"},{"id":"064bc21b-4d02-5987-9c23-08b1ca8870d1","slug":"statins","fullItemName":"Statins"}]},{"id":"05c20737-02bb-500e-b3e6-0a506d19e727","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1ae6e3bc-f751-5c4b-a14d-09c72b74424e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a3e487f8-13d0-532b-b16f-d448106af2ac","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"03c8dfe8-3b8b-5c16-ab71-21f98aa13dcd","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a1919ef1-18db-59ab-8c6d-7ef4d649f5d3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"3e57d884-d476-55de-a85c-a5e4e2001343","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e8c5059d-6ccf-58a3-bb80-1a8273c64c14","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"bcfd412e-e461-5a99-a38f-a03a01873fa5","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"dc552ddd-7106-5f5f-a7d9-4b2d6f80e1fa","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"910df492-c0b0-5a1b-906c-df488547a00e","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 0f7c3303-0832-49b2-b387-8aad86a62d99 --><h3>Previous changes</h3><!-- end field 0f7c3303-0832-49b2-b387-8aad86a62d99 -->","summary":null,"htmlStringContent":"<!-- begin item 9b35add2-e4c4-4d36-ac79-9a1476ab0fe1 --><!-- begin field 8876fcc9-2a73-44fc-9336-61e28a994e3f --><p><strong>October 2015 </strong>— minor update. The Prescribing information section has been updated to include:</p><ul><li>Advice from the Medicines and Healthcare products Regulatory Agency (MHRA) and the drug manufacturers that combination use of drugs from two classes of the renin-angiotensin system (RAS) blocking agents (for example an angiotensin-converting enzyme [ACE] inhibitor <em>plus </em>an angiotensin-II receptor antagonist or aliskiren) is not recommended.</li><li>Other common adverse effects of angiotensin-converting enzyme (ACE) inhibitors, and a drug interaction between ramipril tablets (Tritace<sup>®</sup>) and vildagliptin, based on the manufacturer's Summary of Product Characteristics (SPC) for Tritace<sup>®</sup>.</li><li>The information on beta blockers has been re-worded to reflect advice from the manufacturers' Summary of Product Characteristics, in relation to the cautions and contraindications of beta-blockers if the person has a form of obstructive airways disease.</li></ul><p><strong>June to September 2014 </strong>— reviewed. A literature search was conducted in June 2014 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The main significant changes made to this topic reflect the recommendations from the National Institute for Health and Care Excellence (NICE) 2013 guideline <em>Secondary prevention in primary and secondary care for patients following a myocardial infarction</em> and include:</p><ul><li>Routine use of dual antiplatelet therapy for up to 12 months following a myocardial infarction (MI).</li><li>A greater emphasis on the offering of an exercise-based cardiac rehabilitation programme to people as soon as possible post-MI, and ways to engage greater participation.</li></ul><p><strong>December 2013 </strong>— minor update. Two broken links fixed.</p><p><strong>July 2013 </strong>— minor update. Links to the DVLA website have been updated.</p><p><strong>July 2013 </strong>— minor update. The management of abnormal results in people who is on an angiotensin-converting enzyme inhibitor according to the updated National Institute for Health and Clinical Excellence guideline: <em>Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care.</em></p><p><strong>June 2013 </strong>— minor update. The 2013 QOF options for local implementation have been added to this topic.</p><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>January 2013 </strong>— minor update. Update to the text to reflect safety advice issued by the Medicines and Healthcare products Regulatory Agency for simvastatin.</p><p><strong>November 2012 </strong>— minor update. The links to the electronic medicines website (<a href=\"http://www.medicines.org.uk/\" data-hyperlink-id=\"f8fca2f2-387c-49c2-9dd7-a97000ec3458\">www.medicines.org.uk</a>) have been updated.</p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>March 2012 </strong>— minor update. The 2012/2013 QOF indicators have been added to this topic. Issued in April 2012.</p><p><strong>February 2012 </strong>— minor update. Updated to include the recommendation from the House of Commons Science and Technology Committee that people should have at least two alcohol-free days per week. Issued in March 2012.</p><p><strong>January 2012 </strong>— minor update. Information from the Medicines and Healthcare products Regulatory Agency (MHRA) about the risk of hyperglycaemia and diabetes with statin use has been added. Issued in February 2012.</p><p><strong>May 2011 </strong>— minor update. The 2011/2012 QOF indicators and the 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>March 2011 </strong>— topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made.</p><p><strong>October 2010 </strong>— minor update. Advice about flying for people with atrial fibrillation, based on the British Heart Foundation Factfile, <em>Fitness to fly for passengers with cardiovascular disease</em>, which is derived from the British Cardiovascular Society Working Group's expert guidance has also been included. Issued in October 2010.</p><p><strong>July 2009 </strong>— minor update to clarify the advice from the Medicines and Healthcare products Regulatory Agency on the use of angiotensin-converting enzyme inhibitors and angiotensin-II receptor antagonists in women who are breastfeeding. Issued in July 2009.</p><p><strong>June 2009 </strong>— minor update to the<em>Basis for recommendation</em>, regarding not starting beta-blockers if it is more than 1 year after a diagnosis of myocardial infarction. Issued in June 2009.</p><p><strong>May 2009 </strong>— minor update to include drug safety advice from the Medicines and Healthcare products Regulatory Agency on the use of angiotensin-converting enzyme inhibitors and angiotensin-II receptor antagonists in women who are breastfeeding. Issued in June 2009.</p><p><strong>April 2009 </strong>— updated to include the Quality Outcomes Framework (QOF) indicators for coronary heart disease from the General Medical Services (GMS) contract in the <em>Goals and outcome measures </em>section. Issued in May 2009.</p><p><strong>October 2008 </strong>— minor typographical correction. Issued in October 2008.</p><p><strong>April 2008 </strong>— minor update to text regarding a new product (perindopril arginine). Issued in May 2008.</p><p><strong>March 2008 </strong>— minor update. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued advice regarding several additional class adverse effects of statins. Issued in March 2008.</p><p><strong>January 2008 </strong>— updated. The Medicines and Healthcare products Regulatory Agency (MHRA) has recently advised that ACE inhibitors and angiotensin II receptor antagonists should not be used at any stage of pregnancy, and have also issued updated advice on interactions with statins. Issued in January 2008.</p><p><strong>September to December 2007 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. Updated to reflect the NICE guideline on secondary prevention for people who have had a myocardial infarction. The main change to the recommendations is that people who have had a proven myocardial infarction more than 12 months ago should not be routinely started on a beta-blocker if they have preserved left ventricular function and are asymptomatic, unless they are at increased risk of further cardiovascular events, or there are other compelling indications for beta-blocker treatment.</p><p><strong>October to December 2005 </strong>— reviewed. Validated in March 2006 and issued in May 2006.</p><p><strong>March 2002 </strong>— written. Validated in October 2002 and issued in December 2002.</p><!-- end field 8876fcc9-2a73-44fc-9336-61e28a994e3f --><!-- end item 9b35add2-e4c4-4d36-ac79-9a1476ab0fe1 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}